MA71624A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents

Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Info

Publication number
MA71624A
MA71624A MA71624A MA71624A MA71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A MA 71624 A MA71624 A MA 71624A
Authority
MA
Morocco
Prior art keywords
parp14
therapy
protein degradation
targeted protein
targeted
Prior art date
Application number
MA71624A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Nicholas Robert Perl
Jennifer DOWNING
Original Assignee
Abbvie Operations Singapore Pte. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Operations Singapore Pte. Ltd. filed Critical Abbvie Operations Singapore Pte. Ltd.
Publication of MA71624A publication Critical patent/MA71624A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71624A 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie MA71624A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263393522P 2022-07-29 2022-07-29
US202263420307P 2022-10-28 2022-10-28
US202363443170P 2023-02-03 2023-02-03
EP23758760.5A EP4561999A1 (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
PCT/US2023/028955 WO2024026081A1 (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Publications (1)

Publication Number Publication Date
MA71624A true MA71624A (fr) 2025-05-30

Family

ID=87797850

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71624A MA71624A (fr) 2022-07-29 2023-07-28 Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie

Country Status (13)

Country Link
US (1) US20240101540A1 (fr)
EP (1) EP4561999A1 (fr)
JP (1) JP2025526433A (fr)
KR (1) KR20250055509A (fr)
CN (1) CN119923391A (fr)
AU (1) AU2023312809A1 (fr)
CA (1) CA3262703A1 (fr)
CO (1) CO2025002261A2 (fr)
IL (1) IL318518A (fr)
MA (1) MA71624A (fr)
MX (1) MX2025001060A (fr)
TW (1) TW202417435A (fr)
WO (1) WO2024026081A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240374588A1 (en) 2023-04-07 2024-11-14 Astrazeneca Ab Irak4 protacs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
EP3778590A4 (fr) * 2018-04-09 2021-12-22 ShanghaiTech University Composé ciblant une dégradation protéique, utilisation antitumorale, intermédiaire de celui-ci et utilisation de l'intermédiaire
BR112021025645A2 (pt) * 2019-06-19 2022-02-01 Ribon Therapeutics Inc Degradação de proteína alvo de parp14 para uso em terapia

Also Published As

Publication number Publication date
MX2025001060A (es) 2025-05-02
JP2025526433A (ja) 2025-08-13
AU2023312809A1 (en) 2025-02-06
TW202417435A (zh) 2024-05-01
US20240101540A1 (en) 2024-03-28
KR20250055509A (ko) 2025-04-24
CN119923391A (zh) 2025-05-02
CA3262703A1 (fr) 2024-02-01
EP4561999A1 (fr) 2025-06-04
CO2025002261A2 (es) 2025-03-27
WO2024026081A1 (fr) 2024-02-01
IL318518A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
MA56513A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
IL286462A (en) Protein tyrosine phosphatase inhibitors
EP3931626A4 (fr) Lentilles ophtalmiques pour réduire une progression myopique et procédés pour les fabriquer
EP3958779C0 (fr) Système pour chirurgie guidée par ordinateur
EP3952914A4 (fr) Procédés et compositions pour une dégradation de protéine ciblée
EP3743069A4 (fr) Agents de dégradation de protéines bcl-2 pour le traitement du cancer
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
PL3999119T3 (pl) Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów
EP4179098A4 (fr) Thérapie génique pour encéphalopathie stxbp1
EA202192746A1 (ru) Гетероциклические соединения и их применение
EP4221715A4 (fr) Thérapie anti-inflammatoire périvasculaire pour thrombose veineuse
EP4497062A4 (fr) Prédiction de branche dépendante de la charge
EP4491731A4 (fr) Protéine-glutaminase modifiée
EP4495244A4 (fr) Protéine glutaminase modifiée
ES1318912Y (es) Masajeador
MA71618A (fr) Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie
EP3923911A4 (fr) Utilisation de compositions topiques d'inhibiteur de braf pour le traitement d'une radiodermatite
JP1733503S (ja) 目元マッサージ器
IL318518A (en) Targeted protein degradation of PARP14 for use in therapy
EP4313117A4 (fr) Utilisation de polypeptides adnf en thérapie
IL309072A (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
PL4034661T3 (pl) Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem
EP3960241A4 (fr) Agent thérapeutique pour une infection à flavivirus
EP3807306A4 (fr) Séquence leader pour une expression plus élevée de protéines recombinées
EP3752252A4 (fr) Modulation de variants d'épissage de slamf6 pour le traitement du cancer